Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Assets:
Total expenses for the Year ended March 31, 2017	$ (203,962)	$ (129,625)
U.S. Generic Pharmaceuticals
Assets:
Total expenses for the Year ended March 31, 2017		$ (29,300)
International Pharmaceuticals
Assets:
Total expenses for the Year ended March 31, 2017	(82,600)
Fair value, measurements, nonrecurring
Assets:
Total expenses for the Year ended March 31, 2017	(203,962)
Fair value, measurements, nonrecurring | Intangible assets | U.S. Generic Pharmaceuticals
Assets:
Total expenses for the Year ended March 31, 2017	(72,700)
Fair value, measurements, nonrecurring | Intangible assets | International Pharmaceuticals
Assets:
Total expenses for the Year ended March 31, 2017	(46,206)
Fair value, measurements, nonrecurring | Goodwill | Paladin Canada reporting unit
Assets:
Total expenses for the Year ended March 31, 2017	(82,602)
Fair value, measurements, nonrecurring | Certain property, plant and equipment
Assets:
Total expenses for the Year ended March 31, 2017	(2,454)
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0
Total	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Assets:
Certain segment intangible assets	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | International Pharmaceuticals
Assets:
Certain segment intangible assets	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring | Paladin Canada reporting unit
Assets:
Goodwill	0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0
Total	0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Assets:
Certain segment intangible assets	0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | International Pharmaceuticals
Assets:
Certain segment intangible assets	0
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring | Paladin Canada reporting unit
Assets:
Goodwill	0
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0
Total	112,873
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Assets:
Certain segment intangible assets	27,992
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | International Pharmaceuticals
Assets:
Certain segment intangible assets	0
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring | Paladin Canada reporting unit
Assets:
Goodwill	$ 84,881